Therapeutic strategies for metabolic diseases: small-molecule diacylglycerol acyltrasferase (DGAT) inhibitors = 대사질환 치료제로서의 DGAT 저해제 리뷰

Cited 27 time in scopus
Metadata Downloads
Title
Therapeutic strategies for metabolic diseases: small-molecule diacylglycerol acyltrasferase (DGAT) inhibitors = 대사질환 치료제로서의 DGAT 저해제 리뷰
Author(s)
R Naik; B W Obiang-Obounou; M Kim; Y Choi; Hyun Sun Lee; K Lee
Bibliographic Citation
Chemmedchem, vol. 9, pp. 2410-2424
Publication Year
2014
Abstract
Metabolic diseases such as atherogenic dyslipidemia, hepatic steatosis, obesity, and type?II diabetes are emerging as major global health problems. Acyl-CoA:diacylglycerol acyltransferase (DGAT) is responsible for catalyzing the final reaction in the glycerol phosphate pathway of triglycerol synthesis. It has two isoforms, DGAT-1 and DGAT-2, which are widely expressed and present in white adipose tissue. DGAT-1 is most highly expressed in the small intestine, whereas DGAT-2 is primarily expressed in the liver. Therefore, the selective inhibition of DGAT-1 has become an attractive target with growing potential for the treatment of obesity and type?II diabetes. Furthermore, DGAT-2 has been suggested as a new target for the treatment of DGAT-2-related liver diseases including hepatic steatosis, hepatic injury, and fibrosis. In view the discovery of drugs that target DGAT, herein we attempt to provide insight into the scope and further reasons for optimization of DGAT inhibitors.
Keyword
DGATdiacylglycerol acyltransferasemetabolic disorderssmall-molecule inhibitorstriacylglycerides
ISSN
1860-7187
Publisher
Wiley
DOI
http://dx.doi.org/10.1002/cmdc.201402069
Type
Article
Appears in Collections:
Ochang Branch Institute > Natural Medicine Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.